Clinical use of denosumab for the treatment for postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2807-2812

  Lewiecki, E Michael ^a  

^a Osteoporosis Center   (United States)

Author keywords

Denosumab; FREEDOM; Osteoporosis; Postmenopausal; Safety; Treatment

Indexed keywords

BIOLOGICAL MARKER; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CELLULITIS; CLINICAL TRIAL; CONCUSSION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ECZEMA; ERYSIPELAS; FALLING; FEMALE; FEMUR SHAFT FRACTURE; FLATULENCE; FRACTURE NONUNION; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; KIDNEY FUNCTION; NEOPLASM; NOTE; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; STROKE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; TREATMENT OUTCOME;

EID: 78349272338     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.533651     Document Type: Note

References (44)

1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
2. Cooper C, Campion G, Melton III LJ, Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9
3. European Foundation for Osteoporosis and Bone Disease, National Osteoporosis Foundation. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1-6
4. Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10
5. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
6. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12-17S
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
9. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 1998;280:2077-82
12. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
13. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmeno-pausal osteoporosis. Osteoporos Int 2000;11:83-91
14. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
15. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
17. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
18. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
19. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
20. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
21. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
22. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
23. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
24. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
25. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-65
26. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2009;25:72-81
27. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in post-menopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-61
28. Amgen Inc. Prolia Package Insert. 2010
29. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the path-ophysiology of osteoporosis. Immunol Rev 2005;208:207-27
30. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005;208:19-29
31. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24
32. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogen-esis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-23
33. Stolina M, Dwyer D, Ominsky MS, et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 2007;179:7497-505
34. Stolina M, Dwyer D, Morony S, et al. Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum 2005; 20:S708
35. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348-60
36. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 2010; Epub
37. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25:72-81
38. Reid I, Miller P, Brown J, et al. Effects of denosumab on bone histomorpho-metry: The FREEDOM and STAND studies. J Bone Miner Res 2010;Epub ahead of print; DOI: 10.1002/jbmr.149
39. McCombs JS, Thiebaud P, Laughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
40. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
41. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
42. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. 2004
43. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2010; Epub
44. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010;47:34-40